Previous Close | 7.63 |
Open | 7.66 |
Bid | 4.63 x 1200 |
Ask | 12.00 x 800 |
Day's Range | 7.14 - 7.68 |
52 Week Range | 3.57 - 19.84 |
Volume | |
Avg. Volume | 940,041 |
Market Cap | 1.782B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | 4.31 |
EPS (TTM) | 1.67 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 14.67 |
Subscribe to Yahoo Finance Plus to view Fair Value for LYEL
The mean of analysts' price targets for Lyell Immunopharma (LYEL) points to a 93.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Shareholders in Lyell Immunopharma, Inc. ( NASDAQ:LYEL ) may be thrilled to learn that the analysts have just delivered...
Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 51.61% and 960.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?